Journal article

Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer

Jianling Xie, Eric P Kusnadi, Luc Furic, Luke A Selth

CANCERS | MDPI | Published : 2021

Abstract

Breast and prostate cancer are the second and third leading causes of death amongst all cancer types, respectively. Pathogenesis of these malignancies is characterised by dysregulation of sex hormone signalling pathways, mediated by the estrogen receptor-α (ER) in breast cancer and androgen receptor (AR) in prostate cancer. ER and AR are transcription factors whose aberrant function drives oncogenic transcriptional programs to promote cancer growth and progression. While ER/AR are known to stimulate cell growth and survival by modulating gene transcription, emerging findings indicate that their effects in neoplasia are also mediated by dysregulation of protein synthesis (i.e., mRNA translati..

View full abstract

Grants

Awarded by Victorian Cancer Agency Fellowships by the Department of Health and Human Services


Awarded by National Health and Medical Research Council, Australia


Awarded by Cancer Council of South Australia


Awarded by Hospital Research Foundation


Funding Acknowledgements

E.P.K. and L.F. are supported by Victorian Cancer Agency Fellowships awarded by the Department of Health and Human Services (ECRF20018 and MCRF16007). LF is also supported by a grant from the National Health and Medical Research Council, Australia (APP1141339) and the Victorian Medical Acceleration Fund (VMRAF). L.A.S. is supported by: a Principal Cancer Research Fellowship awarded by Cancer Council's Beat Cancer project on behalf of its donors, the South Australian Government through the Department of Health, and the Australian Government through the Medical Research Future Fund; and grants from the Cancer Council of South Australia (Beat Cancer Project Grant 1185012), the Movember Foundation and the Prostate Cancer Foundation of Australia (Movember Revolutionary Team Award MRTA-3) and The Hospital Research Foundation (C-PJ-126-Exper-2019).